ATE253915T1 - Src-kinase hemmende verbindungen - Google Patents

Src-kinase hemmende verbindungen

Info

Publication number
ATE253915T1
ATE253915T1 AT00941701T AT00941701T ATE253915T1 AT E253915 T1 ATE253915 T1 AT E253915T1 AT 00941701 T AT00941701 T AT 00941701T AT 00941701 T AT00941701 T AT 00941701T AT E253915 T1 ATE253915 T1 AT E253915T1
Authority
AT
Austria
Prior art keywords
inhibiting compounds
src kinase
tyrosine kinase
kinase inhibiting
diseases
Prior art date
Application number
AT00941701T
Other languages
English (en)
Inventor
Helen M Armstrong
Richard Beresis
Joung L Goulet
Mark A Holmes
Xingfang Hong
Sander G Mills
William H Parsons
Peter J Sinclair
Mark G Steiner
Frederick Wong
Dennis M Zaller
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE253915T1 publication Critical patent/ATE253915T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00941701T 1999-06-30 2000-06-26 Src-kinase hemmende verbindungen ATE253915T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14163999P 1999-06-30 1999-06-30
PCT/US2000/017443 WO2001000213A1 (en) 1999-06-30 2000-06-26 Src kinase inhibitor compounds

Publications (1)

Publication Number Publication Date
ATE253915T1 true ATE253915T1 (de) 2003-11-15

Family

ID=22496545

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941701T ATE253915T1 (de) 1999-06-30 2000-06-26 Src-kinase hemmende verbindungen

Country Status (8)

Country Link
US (1) US6498165B1 (de)
EP (1) EP1206265B1 (de)
JP (1) JP2003523942A (de)
AT (1) ATE253915T1 (de)
AU (1) AU5636900A (de)
CA (1) CA2383546A1 (de)
DE (1) DE60006541D1 (de)
WO (1) WO2001000213A1 (de)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740682B2 (en) * 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
AU3704101A (en) * 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US7105530B2 (en) 2000-12-21 2006-09-12 Smithkline Beecham Corporation Pyrimidineamines as angiogenesis modulators
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
WO2003004006A2 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
WO2003004007A2 (en) * 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
JP2004530722A (ja) * 2001-06-29 2004-10-07 アブ サイエンス 骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
ATE401079T1 (de) * 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
DE10135050A1 (de) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
CA2459161A1 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
DE60228278D1 (de) * 2001-09-20 2008-09-25 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
DE60227701D1 (de) * 2001-09-20 2008-08-28 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
CA2463989C (en) * 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
CA2477111A1 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
EA009051B1 (ru) * 2002-06-06 2007-10-26 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. О-замещенные гидроксиарильные производные
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
AU2003284399A1 (en) * 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
AU2003295776B2 (en) * 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
WO2004067516A1 (en) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
OA13151A (en) * 2003-02-26 2006-12-13 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors.
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
WO2005021531A1 (en) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors
NZ545864A (en) 2003-09-22 2009-12-24 S Bio Pte Ltd Benzimidazole derivates: preparation and pharmaceutical applications
US20050107374A1 (en) * 2003-10-21 2005-05-19 Amgen Inc. Substituted heterocyclic compounds and methods of use
ES2578254T3 (es) * 2003-12-03 2016-07-22 Ym Biosciences Australia Pty Ltd Inhibidores de cinasas basados en azol
EP1704145B1 (de) * 2004-01-12 2012-06-13 YM BioSciences Australia Pty Ltd Selektive kinaseinhibitoren
AU2005203919B2 (en) * 2004-01-12 2011-07-21 Ym Biosciences Australia Pty Ltd Selective kinase inhibitors
GB0402138D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP2543376A1 (de) * 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazin Kinasehemmer
JP2008505910A (ja) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
WO2006044453A1 (en) 2004-10-13 2006-04-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
CA2589779A1 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
WO2006066914A2 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
RU2405780C2 (ru) * 2005-02-16 2010-12-10 Астразенека Аб Химические соединения
CN103467471A (zh) 2005-06-06 2013-12-25 武田药品工业株式会社 有机化合物
US20060281764A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20070021435A1 (en) * 2005-06-10 2007-01-25 Gaul Michael D Aminopyrimidines as kinase modulators
EP1896072A4 (de) 2005-06-24 2013-01-09 Univ Duke System zur direkten heilmittelverabreichung auf der basis wärmegesteuerter biopolymere
WO2007025103A2 (en) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
WO2007032445A1 (ja) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
CN101272685A (zh) * 2005-09-27 2008-09-24 Irm责任有限公司 包含二芳基胺的化合物和组合物以及它们作为c-kit受体调节剂的用途
ES2597843T3 (es) * 2005-11-24 2017-01-23 Dompé Farmaceutici S.P.A. Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen
ES2402419T3 (es) * 2005-12-05 2013-05-03 Pfizer Products Inc. Polimorfos de un inhibidor de C-MET/HGFR
AU2006323027B2 (en) * 2005-12-05 2012-08-02 Pfizer Products Inc Method of treating abnormal cell growth
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8871746B2 (en) 2006-03-02 2014-10-28 Kineta Four, LLC Antiviral drugs for treatment of arenavirus infection
EP1988776B1 (de) * 2006-03-02 2012-08-08 Siga Technologies, Inc. Antivirale mittel zur behandlung von arenavirus-infektionen
US7977365B2 (en) 2006-03-02 2011-07-12 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US8246966B2 (en) * 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
ATE543498T1 (de) * 2006-09-08 2012-02-15 Hoffmann La Roche Benzotriazol kinasemodulatoren
JP4958263B2 (ja) * 2006-09-08 2012-06-20 学校法人北里研究所 有機発光性化合物及びその化合物を含有する発光層
EP2081431B1 (de) * 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organische verbindungen
CA2669531A1 (en) 2006-11-22 2008-06-05 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
EP2089034A4 (de) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc Neue verwendungszwecke
CN101547917A (zh) 2006-12-08 2009-09-30 霍夫曼-拉罗奇有限公司 用作jnk调节剂的取代的嘧啶类化合物及它们的应用
CN101583365B (zh) * 2006-12-15 2012-09-26 阿布拉西斯生物科学公司 三嗪衍生物及其治疗应用
AU2007337895C1 (en) * 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
GB0625827D0 (en) * 2006-12-22 2007-02-07 Astex Therapeutics Ltd New compounds
US8895745B2 (en) * 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
CN101622015A (zh) 2007-03-05 2010-01-06 协和发酵麒麟株式会社 药物组合物
EP2170058B1 (de) * 2007-06-20 2013-07-03 Merck Sharp & Dohme Corp. Cetp-hemmer aus benzoxazolarylamiden
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
CA2707218A1 (en) * 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc. Organic compounds
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
MX2010012457A (es) * 2008-05-13 2010-12-07 Irm Llc Heterociclos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa.
EP2283009B1 (de) * 2008-05-16 2012-08-29 F. Hoffmann-La Roche AG Jnk-hemmer
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
EA201170772A1 (ru) 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
MX2011005932A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
CA2740385A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
RU2535217C2 (ru) * 2009-02-06 2014-12-10 Ниппон Синяку Ко., Лтд. Производные аминопиразина и лекарственные средства
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2434895A4 (de) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc Organische verbindungen
BRPI1011961A2 (pt) * 2009-05-29 2016-04-26 Sumitomo Chemical Co agente para o tratamento ou prevenção de doenças associadas com a atividade de fatores neurotróficos.
EP2440053A4 (de) 2009-06-09 2012-10-31 California Capital Equity Llc Benzylsubstituierte triazinderivate und ihre therapeutischen anwendungen
EP2440057A4 (de) 2009-06-09 2012-12-05 California Capital Equity Llc Triazinderivate und deren therapeutische anwendungen
US20110030037A1 (en) * 2009-07-07 2011-02-03 Vadim Olshansky Zone migration in network access
PL2769737T3 (pl) 2009-07-20 2017-08-31 Bristol-Myers Squibb Company Kombinacja przeciwciała anty-ctla-4 z etopozydem w leczeniu synergicznym chorób proliferacyjnych
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
EP2491385B1 (de) 2009-10-20 2017-05-10 DiaTech Holdings, Inc. Proximitätsvermittelte tests für den nachweis von onkogenen fusionsproteinen
WO2011068993A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins.
AU2010339531A1 (en) 2009-12-30 2012-08-23 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2675494B1 (de) 2011-02-17 2016-05-18 Nestec S.A. Vorrichtung und verfahren zur isolierung von leukozyten und tumorzellen durch filtration
TWI572599B (zh) * 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
SG10201702654VA (en) 2011-04-22 2017-06-29 Signal Pharm Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
CN102249922A (zh) * 2011-05-27 2011-11-23 甘肃金盾化工有限责任公司 一种2,3,4,5-四氟苯甲酰基乙酸乙酯的制备方法
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
CN103958506B (zh) 2011-09-27 2017-02-22 诺华股份有限公司 用作突变idh抑制剂的3‑嘧啶‑4‑基‑噁唑烷‑2‑酮化合物
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
JP2015516464A (ja) * 2012-05-15 2015-06-11 カルアジア ファーマシューティカルズ，インコーポレイテッド 細胞質Ｈｓｐ９０の阻害剤としてのピリミジンジアミン誘導体
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EP2956141A4 (de) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc Neuartige verwendungen
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
US9598426B2 (en) 2013-03-15 2017-03-21 Intra-Cellular Therapies, Inc. Organic compounds
MX2015016783A (es) 2013-06-07 2016-07-18 California Inst Biomedical Res Inhibidores de moleculas pequeñas de fibrosis.
KR101809072B1 (ko) 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
EP3039015B1 (de) * 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituierte pyrimidin-bmi-1 inhibitoren
EP3134123B1 (de) * 2014-02-21 2021-02-17 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selektive agonisten in kombination mit einem anti-ctla-4-antikörper oder einem anti-pd-1-antikörper
WO2015196186A1 (en) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Organic compounds
WO2016016894A1 (en) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Media for culturing pluripotent stem cells
TWI686394B (zh) 2014-08-07 2020-03-01 美商內胞醫療公司 有機化合物
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
WO2016063122A1 (en) 2014-10-20 2016-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening a subject for a cancer
EP3229836B1 (de) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Menschliche monoklonale antikörper gegen axl
CA2968874A1 (en) 2014-12-10 2016-06-16 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
WO2016115218A1 (en) * 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
WO2017005847A1 (en) 2015-07-07 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to myosin 18a and uses thereof
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10301255B2 (en) * 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
PL3331863T3 (pl) * 2015-08-03 2020-08-10 Glenmark Pharmaceuticals S.A. Nowe związki jako modulatory ror gamma
ES2955775T3 (es) 2015-08-27 2023-12-07 Inst Nat Sante Rech Med Métodos para predecir el tiempo de supervivencia de pacientes que padecen cáncer de pulmón
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3419999B1 (de) 2016-02-26 2021-08-04 (INSERM) Institut National de la Santé et de la Recherche Médicale Antikörper mit spezifizität für btla und verwendungen davon
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
EP3463433A1 (de) 2016-05-25 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und zusammensetzungen zur behandlung von krebs
WO2017214395A1 (en) 2016-06-10 2017-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN109661406A (zh) 2016-07-29 2019-04-19 国家医疗保健研究所 靶向肿瘤相关巨噬细胞的抗体及其用途
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
HRP20211544T1 (hr) 2016-10-21 2022-01-07 Inserm - Institut National De La Santé Et De La Recherche Médicale Postupci za unapređivanje odgovora t stanica
US20190345500A1 (en) 2016-11-14 2019-11-14 |Nserm (Institut National De La Santé Et De La Recherche Médicale) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
WO2018211007A1 (en) 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
AR112481A1 (es) 2017-08-28 2019-10-30 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
WO2019072888A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF PREDICTING THE THERAPEUTIC RESPONSE IN HEPATOCELLULAR CANCER
WO2019072885A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR20200111168A (ko) 2017-11-24 2020-09-28 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 암 치료를 위한 방법 및 조성물
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019113173A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3720974A1 (de) 2017-12-07 2020-10-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zum screening eines patienten auf einen krebs
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019197683A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
EP3564235A1 (de) 2018-05-03 2019-11-06 Northwestern University Substituierte aromatische n-heterocyclische verbindungen als inhibitoren der mitogen-aktivierten proteinkinase-interagierenden kinase 1 (mnk1) und 2 (mnk2)
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
CN113286589A (zh) 2018-05-30 2021-08-20 大卫·马舒瓦尔 用于治疗癌症的方法和药物组合物
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
US20210236633A1 (en) 2018-08-06 2021-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
US20220047701A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
KR20210065965A (ko) 2018-09-21 2021-06-04 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서 작용화된 헤테로사이클
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3119973A1 (en) 2018-11-21 2020-05-28 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
EP3914698A1 (de) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Kulturmedien für pluripotente stammzellen
EP3924520A1 (de) 2019-02-13 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur behandlung von krebs bei einer krebskranken person
JP2022523544A (ja) 2019-03-06 2022-04-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃｍｍｒｄの診断方法
CN114630838A (zh) 2019-05-20 2022-06-14 法国国家健康和医学研究院 新的抗cd25抗体
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021023650A1 (en) 2019-08-02 2021-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for screening a subject for a cancer
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
EP3800201A1 (de) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h-stimulierung verbessert nk-zellen-abtötungsaktivitäten
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
WO2022162162A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to diagnose msi cancer
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646049A (en) 1970-03-05 1972-02-29 Merck & Co Inc Acylaminobenzimidazole derivatives
US4806649A (en) 1983-08-22 1989-02-21 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3- (pyrrolidinyl)-1H-indazoles
ES2087056T3 (es) 1986-01-13 1996-07-16 American Cyanamid Co 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
AU7759591A (en) 1990-04-13 1991-11-11 Smithkline Beecham Corporation Substituted benzimidazoles
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
DK0672041T3 (da) 1993-10-01 2002-02-25 Novartis Ag Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
WO1995009851A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
EP0672035A1 (de) 1993-10-01 1995-09-20 Novartis AG Pyrimidinaminderivate und verfahren zu deren herstellung
WO1996033194A1 (en) * 1995-04-21 1996-10-24 Neurosearch A/S Benzimidazole compounds and their use as modulators of the gaba a receptor complex
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
WO1999041253A1 (en) 1998-02-17 1999-08-19 Tularik Inc. Anti-viral pyrimidine derivatives
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
DE60006541D1 (de) 2003-12-18
EP1206265B1 (de) 2003-11-12
EP1206265A1 (de) 2002-05-22
EP1206265A4 (de) 2002-08-07
JP2003523942A (ja) 2003-08-12
US6498165B1 (en) 2002-12-24
AU5636900A (en) 2001-01-31
WO2001000213A1 (en) 2001-01-04
CA2383546A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
ATE253915T1 (de) Src-kinase hemmende verbindungen
YU84603A (sh) Novi inhibitori tirozin kinaze
MY143466A (en) Inhibitors of tyrosine kinases
CZ20011394A3 (cs) Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
ATE337312T1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
HUP0402422A2 (hu) Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
NZ508268A (en) Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
PT828728E (pt) Di-hidrobenzofuranos de fenilo
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
HUP0400644A2 (hu) Aszpirint tartalmazó gyógyászati kézítmények

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties